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PRINCIPALES INTERACCIONES 
DIETA-FÁRMACO QUE AFECTAN LA CINÉTICA
Y PROPIEDADAS HIPOLIPEMIANTES
DE LAS ESTATINAS
Resumen
La administración conjunta de estatinas y alimentos
puede producir reacciones adversas, como miopatía o
rabdomiolisis, o reducir su acción farmacológica. Este
artículo revisa las interacciones más importantes entre
estatinas y componentes dietéticos. El consumo de pectina
o de salvado de avena junto con Lovastatina reduce la
absorción del fármaco, mientras que la ingesta de alcohol
no afecta la eficacia ni la seguridad del tratamiento con
Fluvastatina. Algunos componentes del zumo de pomelo
inhiben el citocromo P-450 A4, reduciendo el metabo-
lismo presistémico de la Simvastatina, Lovastatina y
Atorvastatina. Se necesitan estudios de seguimiento sobre
los efectos terapéuticos de las estatinas en pacientes que
consumen dieta Mediterránea para asegurar la correcta
prescripción, ya que no existen estudios de posibles inte-
racciones entre el aceite o sus compuestos minoritarios y
las estatinas. Un estudio preliminar sugiere que el aceite
de oliva respecto al de girasol incrementa la acción hipoli-
pemiante de la Simvastatina. El consumo de aceites ricos
en ácidos grasos poliinsaturados, a través de la activación
de citocromo P-450, podría disminuir la vida media de las
estatinas y, por tanto, sus efectos hipolipemiantes. La
terapia combinada estatinas y ácidos grasos n-3 da lugar
a una interacción farmacodinámica que mejora el perfil
lipídico e induce mayor cardioprotección. Aunque las
estatinas son más efectivas en individuos con alta produc-
ción endógena de colesterol y los esteroles de plantas en
aquellos que presentan mayor absorción de colesterol, la
terapia conjunta induce efectos complementarios muy
positivos. Se concluye la revisión sugiriendo más estudios
en aquellas interacciones entre alimentos (ej. tipos de
aceite de oliva, de zumos, de fibra o el consumo de bebidas
alcohólicas ricas en polifenoles o etanol) y estatinas.
(Nutr Hosp. 2010;25:193-206)
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Abstract
Concomitant administration of statins with food may
alter statin pharmacokinetics or pharmacodynamics, incre-
asing the risk of adverse reactions such as myopathy or
rhabdomyolysis or reducing their pharmacological action.
This paper reviews major interactions between statins and
dietary compounds. Consumption of pectin or oat bran
together with Lovastatin reduces absorption of the drug,
while alcohol intake does not appear to affect the efficacy
and safety of Fluvastatin treatment. Grapefruit juice com-
ponents inhibit cytochrome P-4503A4, reducing the presys-
temic metabolism of drugs such as Simvastatin, Lovastatin
and Atorvastatin. Follow-up studies on the therapeutic
effect of statins in patients consuming a Mediterranean-style
diet are necessary to assure the correct prescription because
the oil-statin and minor oil compound-statin possible inte-
ractions have been only briefly studied. Preliminary study
suggests that olive oil can increase the hypolipaemiant effect
of Simvastatin with respect sunflower oil. The consumption
of polyunsaturated rich oils, throughout the cytochrome P-
450 activation could decrease the half-life of some statins
and therefore their hypolipaemic effects. The statins and n-3
fatty acids combined therapy gives rise to pharmacodinamic
interaction that improves the lipid profile and leads greater
cardioprotection. Although statins are more effective in high
endogenous cholesterol production subjects and plant ste-
rols are more effective in high cholesterol absorption effi-
cacy subjects, plant esterols-statins combined therapy gene-
rates very positive complementary effects. This review ends
suggesting possible diet-stain interactions that require furt-
her investigations (e.g. types of olive oils, fruit juices other
than grapefruit, fibre or consumption of alcoholic beverages
rich in polyphenols or ethanol). 
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Introduction
Statins are drugs that inhibit the rate-limiting
enzyme of cholesterol synthesis 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase, thus reducing intra-
cellular hepatic cholesterol biosynthesis and decrea-
sing intracellular cholesterol accumulation. The
reduction in intracellular cholesterol levels stimulates
synthesis of low density lipoproteins (LDL) receptors
and their expression on the surface of liver cells.
These receptors are responsible for the uptake of LDL
in addition to that of their precursors, very low den-
sity lipoproteins (VLDL) and VLDL remnants, whose
hydrolysis produces LDL. The more VLDL and
VLDL remnants taken up by the receptors, the fewer
LDL produced. This effect of statins on VLDL also
explains their capacity to reduce triglyceride levels,
although to a lesser degree and in a less consistent
manner.1 Nevertheless, statins may also produce
adverse reactions, such as myopathy and rhabdom-
yolysis. Concomitant use of other drugs may lead to
undesirable interactions and increase the risk of
adverse reactions.2 Of the various statins available,
those that are presently marketed in Spain include
Simvastatin, Lovastatin, Pravastatin, Atorvastatin
and Fluvastatin (fig. 1). 
The knowledge of structure and pharmacokinetic
characteristics of these drugs will help to understand
their pharmacokinetically-based interactions with cer-
tain food compounds. Table I summarises the pharma-
cokinetic characteristics of statins, as well as the prin-
cipal transporters involved in their metabolism and
elimination. All statins presently available display
good intestinal absorption. Thus, Simvastatin and
Lovastatin, which are lipophylic, easily cross the
plasma membrane by means of passive diffusion,
while other statins are recognised by specific transport
systems. Pravastatin is the least lipophylic statin.2,3
Simvastatin, Lovastatin, Pravastatin, Atorvastatin and
Pitavastatin are P-glycoprotein (Pgp) substrates. The
Pgp is a membrane glycoprotein which plays an impor-
tant role during the cellular capture of drugs.3
The statins presently available are mainly eliminated
by the liver. Except for Pravastatin, of which up to 47%
is eliminated through urine in an unaltered form, uri-
nary excretion of statins is limited (table I). Organic
anion transporter OAT3 may be involved in renal Pra-
vastatin uptake.3
Simvastatin, Lovastatin and Atorvastatin are meta-
bolised by cytochrome P-450 3 A4 (CYP 3 A4), while
Fluvastatin is metabolised by CYP 2 C9. Only small
amounts of Pravastatin, Rosuvastatin and Pitavastatin
are metabolised; their plasma clearance depends on
transporters involved in hepatic uptake and bile excre-
tion. Hepatic uptake by transporters also plays an
important role in clearance of other statins administe-
red in acid form (Fluvastatin and Atorvastatin).3
A pharmacological interaction is defined as an alte-
ration of the pharmacodynamics and/or pharmacokine-
tics of a drug, produced by concomitant pharmacologi-
cal treatment, dietary factors or social habits such as
tobacco or alcohol.4 Such interactions can affect statins
as much as any other drugs resulting in higher risk of
adverse reactions in some cases or lower pharmacolo-
gical action in others. This review summarises major
data available on nutritional interactions with statins,
placing special emphasis on those interactions that pro-
duce an additive effect to statin treatment.
Statins and dietary fibre
Although the effects of fibre on cholesterol levels
have been thoroughly investigated and its benefits pro-
ven,5 studies have shown that its consumption together
with Lovastatin reduces intestinal absorption of the
drug. In one study6 it was found that after addition of
pectin (three patients) or oat/bran (two patients) to
Lovastatin (80 mg/day), the LDL-c levels were increa-
sed after 4 weeks and returned to their previous values
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Fig. 1.—Chemical structure of main
statins.
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after the consumption of fibre was stopped. Later, it was
observed that the combination of Lovastatin with psy-
llium lowered LDL-c more than the statin alone. Agra-
wal et al.7, in a 4-week parallel study involving 36 male
adults, in which subjects consumed 20 mg of Lovastatin,
10 g of psyllium or 20 mg Lovastatin plus 10 mg psy-
llium, observed an additive effect of the combination,
although the differences were not significant. In a 12-
week blinded placebo-controlled study, patients were
randomized to receive 20 mg of Simvastatin plus pla-
cebo, 10 mg of Simvastatin plus placebo, or 10 mg of
Simvastatin plus 15 g of psyllium daily.8 The effect on
lipid profile was evaluated at 4 and 8 weeks. It was con-
cluded that dietary psyllium supplementation in patients
taking 10 mg Simvastatin is as effective in lowering
LDL-c and ApoB as 20 mg of Simvastatin alone. Values
of HDL-c and TG did not significantly vary by the fibre
addition. In this context, the National Cholesterol Edu-
cation Program (NCEP) Adult Treatment Panel III (ATP
III) guidelines recommend increase soluble fibre (10-25
g daily) as a therapeutic option to enhance LDL-c lowe-
ring.9 Viscous fibre may have additional side effects
reducing blood glucose. Besides, it is important to take
into account the dietary fibre, because administration of
Lovastatin with food is recommended as under those
conditions plasma concentrations are 50% higher than at
fasting conditions.10
Statins and alcoholic beverages
Moderate consumption of alcohol is known to have
beneficial effects on cardiovascular disease, probably
by increasing HDL-c levels. However, high consump-
tion displays deleterious effects giving rise to hyper-
triglyceridaemia.11
Few studies have been carried out to determine the
possible interactions between alcohol and statins (table
II). A prospective crossover study investigated the
effect of acute alcohol consumption together with a
single 40 mg oral dose of Fluvastatin.12 After being ran-
domly divided into two groups, individuals in one
group were given a total of 70 g of ethanol in separate
doses diluted to 20% with orange juice, while those of
the other group were given orange juice alone. Volun-
teers given alcohol showed that the half-life (t1/2) of the
single dose of Fluvastatin was significantly shorter
than that of the controls, whereas the area under the
curve (AUC), the maximum concentration (C
max
), and
the time to reach maximum concentration (T
max
) did not
differ from the control group. The alterations in the
lipoprotein profile, measured after 8 hours, were obser-
ved when the statin was taken with alcohol. Triglyce-
ride levels increased, total cholesterol and LDL-c
levels decreased, possibly due to a pharmacokinetic
interaction, and HDL-c and Apo A1 values slightly
decreased.12 In contrast, the lipoprotein profile measu-
red after 8 hours in the control group did not vary and
only a slight reduction in Apo A1 was observed. 
To evaluate the long-term effect of alcohol consump-
tion, a prospective, double-blind crossed study involving
26 individuals with primary hypercholesterolaemia and a
control group was carried out.13 Patients receiving Flu-
vastatin (40 mg/day) for 6 weeks were divided at random
into two groups; one was given 20 g of alcohol diluted to
20% with lemonade while the other was given lemonade
alone. Alcohol intake tended to increase the half life (t1/2),
the area under the curve (AUC) and the time to reach
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Table I
Pharmacokinetic characteristics of statins
Parameter Fluvastatin Pravastatin Lovastatin Simvastatin Atorvastatin
Absorption (%) 98 34 30 60-80 30
Solubility Fat soluble Water soluble Fat soluble Fat soluble Fat soluble
Bioavailability (%) 19-29 18 5 < 5 12
Prodrug No No Yes Yes No
Proteins bind (%) > 98 50 > 95 > 95 > 98
Main metabolic pathway CYP2C9 Conjugation CYP3A4 CYP3A4 CYP3A4
Active metabolites No No Yes Yes Yes
Half-life (hrs) < 1 1-3 2-4 2-3 11-14
Unmodified urinary excretion (%) NS 47 10 NS < 2
Transporters involved in liver BSEP OATP1B1 OATP1B1 OATP1B1 OATP1B1
uptake and bile excretion OATP2B1
OAT3
BSEP
BCRP
MDR1
MRP2
NS, Non-significant; BSEP, Bile salt exporting pump OATP, Organic anion transporting polypeptide system; OAT, Organic anion transporter;
MRP, Multidrug resistance associated protein; MDR, Multidrug resistance protein; BCRP, Breast cancer resistance protein. Modified from Len-
nernas and Fager.3
maximum concentration (T
max
) compared with control
values, while it did not appear to affect maximum con-
centration values (C
max
). With regard to the lipoprotein
profile, both groups displayed a decrease in total choles-
terol, LDL-c and Apo B, and no significant differences
between the decreases in the two groups were observed,
while HDL-c and triglyceride levels displayed no signifi-
cant changes. Although alcohol modifies the metabolism
of the drug, it does not reduce its efficacy as a hypolipida-
emic agent.13
In conclusion, alcohol consumption does not affect
the efficacy and safety of Fluvastatin treatment, alt-
hough the effect of large doses of alcohol over long
periods of time requires further investigation. Moreo-
ver, the concomitant effect of minor compounds pre-
sent on alcoholic beverages (e.g. trans-resveratrol in
red wines) on statin pharmacokynetics have not yet
been investigated.
Statins and grapefruit juice
The first article to report an interaction between gra-
pefruit juice and a drug appeared in 1989. This acci-
dental finding, made by Bailey et al.14 while studying
the haemodynamic effect of felodipine and ethanol,
was due to the use of grapefruit juice to disguise the fla-
vour of ethanol.
Grapefruit juice interacts with various drugs,15 inclu-
ding calcium channel blockers, antihistamines, immuno-
suppressants, hypnotic benzodiazepines, and the HMG-
CoA reductase inhibitors statins. The interaction
mechanism is believed to be the irreversible inhibition
that grapefruit juice produces on the intestinal cytochrome
P-450 (CYP) 3A4, leading to a reduction of the presyste-
mic metabolism of the drug, elevating its bioavailability.
Alternative mechanisms of this interaction and the possi-
ble responsible compounds in the grapefruit juice are pre-
sented with more detail at the end of this section.
The pharmacokinetic effects of grapefruit juice on
the various statins have been investigated in different
studies carried out by Lilja et al.16-18 (table III). In one
two-phased crossover study,16 10 healthy volunteers,
divided at random into two groups, drank 200 ml gra-
pefruit juice or water three times a day for two days. On
the third day, each volunteer took 40 mg of Simvastatin
with 200 ml of grapefruit juice or water and another
200 ml of the same liquid 30 minutes and 90 minutes
after Simvastatin intake. The results of this study show
an increase in the Cmax and the AUC of Simvastatin in
volunteers who drank grapefruit juice. C
max
values and
AUC also increased with the acid form of Simvastatin.
The authors conclude that grapefruit juice increases
serum concentrations of both, the lactone and acid
form of Simvastatin, and suggest that the probable
mechanism of action is the reduction of the presyste-
mic metabolism of Simvastatin due to the inhibition of
CYP 3A4. These findings indicate that concomitant
administration of grapefruit juice and Simvastatin, at
least in large quantities of the juice, should be avoided,
or that the dose of Simvastatin should be reduced to
avoid adverse reactions such as rhabdomyolysis.16
In a later study, the same research group17 studied the
effect of grapefruit juice on the pharmacokinetics of
Atorvastatin and Pravastatin, using similar design as in
the previous study. Grapefruit juice significantly increa-
ses serum concentrations of Atorvastatin, in both its acid
and lactone forms. Thus, concomitant administration of
Atorvastatin and grapefruit juice should be avoided, or
the dose of Atorvastatin reduced proportionately.16
Nevertheless, this juice does not appear to have any
effect on the pharmacokinetics of Pravastatin due to its
hydrosolubility. A Japanese study also confirmed the
interaction of grapefruit juice with Atorvastatin but not
with Pravastatin.19 It has been also found that Pitavasta-
tin, unlike Atorvastatin, appears to be scarcely affected
by the CYP 3A4-mediated metabolism.20
However, there is a debate concerning duration of the
inhibitory effect of grapefruit juice on CYP 3A4 and the
real effect in hypercholesterolaemic patients. It should be
considered, on one hand the amount of grapefruit juice,
its concentration and frequency of consumption, and on
the other that the variability of the individual response to
the statin-fruit juice interaction is very high,21-22 which
may be explained by genetic variability.
Repeated consumption of high quantities of grape-
fruit juice has increased the AUC values of Simvastatin
considerably.16 However, drinking daily 250 ml of the
juice 12 h apart from Lovastatin has a modest effect on
the pharmacokinetic of the drug.23
196 M. P. Vaquero et al.Nutr Hosp. 2010;25(2):193-206
Table II
Summary of results obtained in studies on the effect of simultaneous alcohol and fluvastatin intake
Changes in pharmacokinetic parameters Lipoprotein profile changes
compared with control group values Control group Study group
Study 1 ↓t 1/2
Single dose Fluvastatin No significant changes in AUC, Slight ↓ Apo A-1 ↓ CT and LDL-c, slight ↓ HDL-c and Apo A-1  
plus alcohol or placebo t 
max
and C 
max
No significant changes in  Triglycerides
Study 2 Tendency to t 1/2, AUC, t max ↓ CT, LDL-c and Apo B ↓ CT, LDL-c and ApoB
Daily dose Fluvastatin for No significant changes in C
max
No significant changes in HDL-c No significant changes in HDL-c, TG
6 months plus alcohol or placebo and  Triglycerides
Source, Smith et al.12,13
In a crossover study using 40 mg of Simvastatin
with water (control period) and with high doses of
grapefruit juice (200 ml three times a day for three
days), or 1, 3 and 7 days after drinking the large quan-
tities of grapefruit juice24 it was observed that when
Simvastatin was taken with grapefruit juice, Simvas-
tatin C
max
and AUC increased 12 and 13.5-fold, res-
pectively, in comparison with control values. When
Simvastatin was administered 24 hr after the last gra-
pefruit juice intake, C
max
and AUC increased 2.4- and
2.1-fold, respectively, compared with control values.
When Simvastatin was given 3 days after the grape-
fruit juice, C
max
and AUC increased 1.5- and 1.4-fold,
respectively, in comparison with control values.
There were no differences between C
max
and AUC
values of study participants who took Simvastatin 7
days after taking grapefruit juice and controls. Furt-
hermore, when Simvastatin was taken 24 hours after
large amounts of grapefruit juice the AUC is much
lower that the one observed after a concomitant intake
of both. The potential interaction of large amounts of
grapefruit juice with CYP 3A4 disappears 3-7 days
after the last intake of grapefruit juice.24
Given that Simvastatin, Lovastatin and Atorvastatin
are metabolised by CYP 3A4 (table I), they are the only
available statins affected by this particular interaction,
for which reason one of the other statins (e.g. Pravasta-
tin, Pitavastatin) can be taken as an alternative treat-
ment.
However, a number of studies focus on other inte-
raction mechanisms besides that of CYP 3A4. Grape-
fruit juice also inhibits P-glycoprotein, a transporter
that carries drugs from the enterocyte back to the gut
lumen, resulting in a further increase in the fraction of
drug that is absorbed.16,25 Grapefruit juice is also capa-
ble to inhibit human organic anion-transporting poly-
peptide B (OATP-B) in vitro.25-26 This inhibition decre-
ases the intestinal uptake and therefore the oral
bioavailability of the drug, which is the opposite effect
to that of CYP 3A4 inhibition. Nevertheless, it remains
unclear the contribution to the bioavailability of statins
affected by P-glycoprotein and OATP-B inhibition.
In 2007, Li et al.27-28 described an estearase inhibition
attribute of grapefruit juice as a new drug interaction.
Lovastatin (a lactone) is known to be metabolized by
CYP 3A4 but also by estearase to a hydroxyacid analog
(active drug). The hydrolysis occurs in gut, liver and
plasma and is considered its major metabolic pathway.
The study carried out in rats and Caco-2 cells demons-
trated that the grapefruit juice decreased Lovastatin
hydrolysis in the gut, and thereby markedly increased
the metabolic stability and permeability of the ester,
leading to the enhancement of exposure to Lovastatin
acid in rats. It was also found that the contribution of
estearase inhibition was similar to that of CYP 3A, and
that the estearase inhibition also affected Analapril (a
prodrug for the treatment of hypertension) pharmaco-
kinetics. 
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Table III
Effect of grapefruit juice (GFJ) on statin pharmacokinetics and recommendations
Reference Statin Treatments Effects Recommendations
Lilja et al.16 Simvastatin 200 ml GFJ 3 times/day. On _ C
max
and _ AUC of statins Avoid concomitant use of GFJ
the third day 40 mg of Simvastatin (lactone and acid forms) and Simvastatin, or reduce
with the first GFJ intake Simvastatin dose
Lilja et al.17 Atorvastatin 200 or 250 ml GFJ 3 times/day. _ C
max
and _ AUC (0-48 h) Use Pravastatin which presents
Fukazawa et al.19 Pravastatin On the third day Atorvastatin of Atorvastatin little or not interaction with GFJ,
(10 or 20 mg) or Pravastatin (10 mg) No significant changes in or reduce Atorvastatin dose
with the first GFJ intake Pravastatin pharmacokinetics
Ando et al.20 Atorvastatin 250 ml GFJ 3 times/day for 4 _ AUC of Pitavastatin acid was Use Pitavastatin
Pitavastatin days. On each day 20 mg of only 13% while that of Atorvastatin
Atorvastatin or 4 mg Pitavastatin was 83%
with the first GFJ intake
Rogers et al.23 Lovastatin 250 ml GFJ once daily for 3 No significant changes in Lovastatin Lovastatin taken 12 h apart 
days 12 h apart from Lovastatin pharmacokinetics. High variability form GFJpresents a modest 
in the individual response interaction
Lilja et al.18 Simvastatin 200 ml GFJ once daily for 3 _ C
max
and _ AUC (0-24 h) Even one glass of GFJ increases
days. On the third day 40 mg Simvastatin plasma concentrations
of Simvastatin with the GFJ intake
Lilja et al.24 Simvastatin 200 ml double-strength GFJ 3 _ C
max
and _ AUC was lower when The interaction of large amounts
times/day for 3 days with 40 mg Simvastatin was taken after 24 h of GFJ with Simvastatin disappears 
Simvastatin, or 1, 3, and 7 days of GFJ intake, even less after 3 days, after 3-7 days 
after ingestion of the high-dose GFJ. and not significant after 7 days
↓ ↓
↓
↓
↓
↓ ↓
↓ ↓
The potential interaction between specific grape-
fruit juice components has been also investigated.28-29
In one study, it was observed that the most powerful
inhibitor of P-glycoprotein was the furanocoumarin
6,7-epoxy-bergamottin, followed by 6,7-dihydroxy-
bergamottin, while bergamottin did not display any
inhibitory effect at concentrations of up to 10 μmol.
Naringenin was 10 times more powerful than narin-
gin. Concentrations of the flavonoids and furano-
coumarins evaluated in this study were in the same
range as those found in grapefruit juice. Therefore,
the results obtained from this in vitro study suggest
that the compounds present in grapefruit juice are
able to inhibit P-glycoprotein modifying the bioa-
vailability of drugs such as Simvastatin, Lovastatin,
Pravastatin, Atorvastatin and Pitavastatin, which are
substrates for that glycoprotein.3 Heating grapefruit
juice was recently found to decrease its concentra-
tions of bergamottin and dihydroxybergamottin, the-
reby decreasing its interactions.30 This finding could
be very useful to those patients who wish to drink
this juice but are taking one of the drugs that interact
with it. 
Concerning the juice components responsible of the
estearase inhibition, the furanocumarins bergamottin,
6,7-dihydroxybergamottin, and bergapten, and the gly-
coside flavonoids naringin and hesperidin, did not pre-
sent estearase inhibition at concentration found in gra-
pefruit juice or higher.28 However, the flavonoid
aglycones morin, galangin, kaemferol, quercetin, and
naringenin showed appreciable estearase inhibition. It
should be pointed out that these compounds are widely
distributed among fruit juices.
There are few studies on the possible interactions
between fruit juices other than grapefruit and statins.
Citrus juices have been found to interact with statins
through the OATP mechanism.31 Orange juice increa-
ses Pravastatin AUC, without affecting its excretion
rate.31 This effect could be related to higher intestinal
absorption of the drug, mediated by the orange juice,
but the mechanism is not clear and further studies are
necessary. Orange juice does not alter Simvastatin
pharmacokinetics.32
One report highlights the possible interaction bet-
ween Rosuvastatin and pomegranate juice causing
rhabdomyolysis in one patient.33 The patient was tre-
ated for familiar hypercholesterolemia with Ezeti-
mide 10 mg/day and Rosuvastatin 5 mg every other
day for 17 months. Three weeks before urgent pre-
sentation, and after reading the consumer informa-
tion on the antioxidant benefits of pomegranate juice,
he began drinking 200 ml twice weekly. Although
the precise influence of this juice was not studied
since this was only a case report, this observation
deserves further research, including the impact of the
media on patient’s choice. These data point out that
health claims of food and ingredients should be tho-
roughly evaluated considering all aspects of the tar-
get population.
Statins and unsaturated fatty acids
Statins and unsaturated oils
Very little information exists on the possible relation
between unsaturated oil intake and statin effects. This
is surprising because culinary oils contribute with more
than 50% of the consumed fat.11 It has been known for
many years that diets rich in fat and cholesterol tend to
raise serum cholesterol.34-36 Monounsaturated fatty
acids (MUFA) are considered neutral because they do
not raise or lower the plasma cholesterol. However,
recent studies show that replacing saturated fatty acids
(SFA) with either MUFA or polyunsaturated fatty
acids (PUFA) lowers total and LDL-c.37,38 Mattson and
Grundy35 found that oleic acid lowered plasma choles-
terol as much as linoleic acid. According to Dietschy,39
unsaturated fatty acids (oleic acid more than linoleic
acid) increase gene expression of LDL receptors, main-
taining the amount and activity of these receptors high
and thus decreasing the concentration of serum LDL,
while palmitic acid in the liver maintains gene expres-
sion of LDL-receptors low and, thus, serum LDL con-
centrations high. However, it is generally accepted a
more prominent hypocholesterolemic effect of n-6
PUFA (e.g. linoleic acid) than of MUFA (e.g. oleic
acid).40,41 Nonetheless, oleic acid keeps HDL-c higher
than linoleic acid does.40,41
Taking into consideration all these results, our rese-
arch group42 carried out a observational follow-up
study in 25 men aged 45 to 65 years presenting accor-
ding to the ATPIII protocol a cardiovascular risk hig-
her than 20%. Twelve of the volunteers used daily, as
the only culinary fat, olive oil; while the other thirteen
volunteers used sunflower oil. After hypercholestero-
laemia diagnosis, the participants were given statins
for the first time. It was confirmed that statins, with
independence of the consumed culinary oil, signifi-
cantly reduced serum lipid and lipoprotein levels after
6 months of treatment. No significant differences on
cholesterol, LDL-c, HDL-c and triglycerides were
found at the start and six months later between the two
oil groups. TC/HDL-cholesterol and the ATPIII 10-
year risk percent significantly decreased more in the
olive oil group. TC and the TC/HDL-cholesterol and
the LDL-cholesterol/HDL-cholesterol ratios and the
ATPIII 10-year risk percent decreased significantly
more in the olive oil-group after BMI, energy and alco-
hol intakes were adjusted. Figure 3 shows the differen-
ces found in volunteers consuming Simvastatin and
olive oil or sunflower oil. This result is relevant taken
into account the predictive power of future cardiovas-
cular risk of the TC/HDL-cholesterol ratio.43
At present no clear explanation can be drown taken
into consideration the theoretical higher hypocholeste-
rolaemic effect of linoleic acid than the oleic acid.40,41
However, PUFA have been shown to activate CYP
activity, while SFA exert lower cytochrome activation
with MUFA exerting intermedium effect.44 Thus, we
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suggest that the half-life of statins could be reduced due
to a cytochrome-activating effect when the drug is con-
sumed by patients following a sunflower oil rich diet
with respect to the same diet prepared with olive oil.
Nonetheless, the possible potentiating effect of olive
oil polyphenols on statin pharmakocynetic, due to an
inhibition of CYP,44,45 should not be ruled out. In the
Sánchez-Muniz et al preliminary paper,42 it was con-
cluded that although Simvastatin was a very effective
hypolipaemic drug, olive oil-diets in preference to sun-
flower oil-diets should be consumed in patients with
high cardiovascular risk.
Statins and n-3 fatty acids
Humans cannot produce n-3 fatty acids, for which
reason they are essential and must be obtained from the
diet. Eicosapentaenoic acid (EPA) is the precursors of
a group of eicosanoids, including prostaglandins
(PGE3, PGD3), prostacyclins (PGI3), thromboxanes
(TXA3) and leukotrienes (LTB5), with anti-inflamma-
tory, antithrombotic, antiarrhythmic and vasodilating
properties.47 Numerous studies have demonstrated the
cardioprotective effect of n-3 fatty acids,48,51 throughout
reduction of TXA2 formation,11 and the increased synt-
hesis of TXA3 and PGI3.52,53 N-3 fatty acids decrease
formation of serie 4-leukotrienes by monocytes and
neutrophils, attenuating leukotriene-mediated chemo-
taxis and the adherence of neutrophils to endothelial
cells. They also reduce the formation of platelet deri-
ved growth factor,54 decreasing the proliferation of
endothelial cells in the process of atherosclerosis,
lower plasma fibrinogen levels55 and arterial pressure
in individuals with hypertension.56
Results of the ATTICA Study57 showed that fish
consumption was inversely related to all the inflamma-
tory markers analysed, especially protein C reactive
and interleukine-6, followed by tumour necrosis fac-
tor-α and the white blood cell count. 
The anti-arrhythmic properties of n-3 fatty acids
may constitute another protective mechanism against
cardiovascular disease.58 Fish intake reduced the risk of
sudden cardiac death in some studies.48,49 Moreover, n-3
fatty acids are able to alter cardiac electrophysiology
and, thus, behave as pro or anti-arrhythmic agents,
depending on the mechanism of the arrhythmia.58 Sta-
tins also display anti-arrhythmic properties, as it is
shown in different studies.59-61 While this action mecha-
nism of statins are not yet entirely clear, it appears that
they may produce these effects due to their anti-inflam-
matory62 or anti-oxidant properties.63
The cardiovascular protective role of statins can be
explained by their capacity to inhibit HMGCo-A
reductase and reduce LDL-c levels in blood. Moreover,
HMGCo-A reductase inhibitors are also known to inhi-
bit transendothelial migration of neutrophils, as well as
to alter the chemotactic capacity of monocytes.64 In
addition, statins can also prevent cardiovascular dise-
ase through other mechanisms. These drugs inhibit
synthesis of mevalonic acid, a precursor of cholesterol
and other metabolites such as isopentenyl adenosines
(which form part of tRNA) and dolichols (used in gly-
coprotein and CoQ10 synthesis). Furthermore, meva-
lonic acid metabolites, such as farnesyl pyrophosphate
and geranyl pyrophosphate, mediate the prenylation of
some specific proteins that intervene in transduction
processes of cellular differentiation and proliferation.
Thus, statins may protect against atherosclerosis by
modulating cell function set into motion by the inhibi-
tion of protein prenylation.2
Statins and n-3 fatty acids have different but comple-
mentary effects on the lipid profile. While statins funda-
mentally reduce concentrations of cholesterol,65-66 n-3
fatty acids reduce plasma triglyceride levels, especially
in individuals with hypertriglyceridaemia.67 A recent
review of studies in humans68 reported that 1.5 to 3.5
g/day of n-3 fatty acids reduce plasma triglyceride con-
centrations by 25-30%, and that the majority of studies
found reductions in total cholesterol and increases in
HDL-c while the results on LDL-c are not consistent.
Therefore, the association of statins with n-3 fatty acids
could be useful to treat dyslipaemias characterised by
high cholesterol and triglyceride levels.
Administered together, statins and n-3 fatty acids
have proven to be safe, effective and well tolerated in
treatment of combined dyslipaemia (table IV). In a
study undertaken by our group,69,70 individuals having
chronic statin therapy who consumed a fish-rich diet
presented a better lipoprotein profile than those who
ate a meat-based diet. In addition, a fish-rich diet is
known to increase insulin sensitivity without the
adverse effects of supplements containing high doses
of n-3 fatty acids.68
In 32 patients with combined dyslipaemia,71 the
addition of n-3 fatty acids to Pravastatin produced
lower triglyceride and Apo B levels than Pravastatin
treatment alone, although the differences were not sta-
tistically significant. On the other hand, total choleste-
rol values were significantly lower when Pravastatin
was used with fish oil than when fish oil was given
alone. Another study concluded that Simvastatin and
n-3 fatty acids have an additive effect and that their
combined therapeutic use probably has beneficial cli-
nical consequences.72 When n-3 fatty acids were com-
bined with Simvastatin treatment, total cholesterol and
triglyceride levels decreased, while HDL-c concentra-
tions were not affected. Apo A and Apo B values did
not change, but Apo E concentrations decreased signi-
ficantly. 
The combined Simvastatin and n-3 fatty acid treat-
ment reduced serum concentrations of total choleste-
rol, triglycerides and Apo E, as reported in previous
studies.72 During postprandial hyperlipaemia, which
decreased with both treatments (although significantly
more with the combined treatment), activation of coa-
gulation factor VII was significantly lower, indicating
that combined treatment may reduce the thrombotic
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potential associated with intake of high-fat meals in
these patients.73 Similar studies were carried out in
patients treated with Atorvastatin. Nordøy et al.74 in a
parallel-group, double-blind, placebo-controlled study
found that postprandial levels of activated factor VII
decreased with Atorvastatin treatment and diminished
even further by the addition of n-3 fatty acids, which
lowered the fasting and postprandial levels of activated
factor VII, and its coagulant activity as well. Prothrom-
bin fragment 1+2 increased during postprandial hyper-
lipaemia, but to a lesser degree after combined treat-
ment with Atorvastatin and n-3 fatty acids. Therefore,
although patients with combined hyperlipaemia pre-
sent an elevated risk of activation of the coagulation
system, especially during postprandial hyperlipaemia,
combined statin and n-3 fatty acid therapy can signifi-
cantly reduce this activation.74 In another study, 59
patients with coronary heart disease who received Sim-
vastatin (10-40 mg/day) were divided at random into
two groups for a one-year period, during which time
one group received n-3 fatty acids while the other was
given placebo.75 The addition of n-3 fatty acids signifi-
cantly lowered serum triglyceride levels by 28% in 12
weeks, and by 35% after 48 weeks of treatment. In
addition, VLDL-c concentrations significantly decrea-
sed and non-HDL-c levels dropped by 18% after 18
weeks of treatment.75 Nordøy et al.76 also concluded
that the addition of low doses of n-3 fatty acids to Ator-
vastatin treatment could improve the cardiovascular
disease risk profile in patients with combined hyperli-
paemia. 
Results regarding the efficacy of combined treat-
ment with statins and n-3 fatty acids indicate that it is a
useful therapeutic alternative in patients with hyper-
triglyceridaemia when LDL levels have decreased and
statin monotreatment cannot lower hypertriglyceridae-
mia. As Simvastatin is extensively metabolised by
CYP 3A4, McKenney et al.77 designed a random and
double-crossed study, with two 14-day-long treatment
periods separated by a wash-out period, to determine
the impact of administration of n-3 fatty acids on Sim-
vastatin pharmacokinetics. Participants were randomly
divided into groups that received 80 mg of Simvastatin
together with a daily morning dose of n-3 fatty acids or
alone. No statistically significant differences in phar-
macokinetic parameters of Simvastatin or its metabo-
lite β-OH-Simvastatin were observed when Simvasta-
tin was administered with n-3 fatty acids, making it
possible to conclude that repeated doses of n-3 fatty
acids do not affect Simvastatin pharmacokinetic.
Nevertheless, after the first dose of fatty acids, the
AUC of Simvastatin increased slightly. The authors of
this study concluded that concomitant treatment with
n-3 fatty acids and Simvastatin did not significantly
affect the pharmacokinetics of Simvastatin in the sta-
tionary state and was well tolerated in the population
studied.77
Statins and phytosterols 
Sterols are a group of components essential to the
formation of animal and plant cell membranes. Phytos-
terols are plant sterols and are differentiated from cho-
lesterol by their lateral chain (fig. 2). Stanols are satura-
ted sterols that lack the double bond in position 5 of the
B ring. The most abundant dietary phytosterols are β-
sitosterol, campesterol and stigmasterol.78
After the discovery of free phytostanols and their
application to reduce cholesterol levels, investigations
of fat-soluble phytostanol esters began in 1991,79 and
phytostanol-enriched margarine became available to
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Table IV
Summary of the results obtained in studies on the combined use of statins and n-3 fatty acids
Reference Number of participants (n) Dyslipemia Treatment Effects of combined treatment
Contacos et al..71 32 Combined hyperlipaemia Pravastatin plus ↓Triglycerides
n-3 ↓Apo B
↓Total cholesterol
Nordøy et al.72 41 Combined hyperlipaemia Simvastatin plus ↓Triglycerides 
n-3 ↓Apo E
↓Total cholesterol 
Nordøy et al.73 41 Combined hyperlipaemia Simvastatin plus ↓Triglycerides
n-3 ↓Apo E
↓Total cholesterol 
↓ Factor VII a
Nordøy et al.74 42 Combined hyperlipaemia Atorvastatin plus ↓ Factor VII a 
n-3
Durrington et al.75 59 Coronary arterial disease Simvastatin plus ↓Triglycerides
and hypertriglyceridaemia n-3 ↓VLDL-c
the general public in 1995.80 A 1992 study demonstra-
ted that a dose of 1.5-3 g/day of phytosterols/phytosta-
nols reduced total plasma cholesterol by 8-17% and
LDL-c by 9-19%, while HDL-c levels were not affec-
ted.81 A subsequent meta-analysis of 41 assays confir-
med those findings and also demonstrated an additive
effect when they were taken with cholesterol-reducing
drugs.82 The most important possible negative effect of
phytosterol intake may be the reduction of fat-soluble
vitamin plasma levels,78,83 which can be avoided, at
least partially, with a fruit and vegetable-rich diet. 
Phytosterols impede cholesterol absorption while
statins inhibit cholesterol synthesis. Both mechanisms
work in a complementary manner to increase LDL
receptor activity and LDL-c plasma clearance. Statins
are most effective in individuals with high endogenous
cholesterol production, while plant sterols act best in
those with the most efficient cholesterol absorption.82
The Scandinavian Simvastatin Survival Study (4S)
demonstrated that individuals with the greatest choles-
terol absorption efficiency and low cholesterol synthe-
sis levels presented high blood phytosterol concentra-
tions and were not able to reduce LDL-c levels or
cardiovascular disease rates after 5 years of statin treat-
ment.84 Keeping in mind the effects of both, phytoste-
rols and statins, the ideal therapy may include small
doses of statins with phytosterols/phytostanols. The
combined treatment will be most efficient in indivi-
duals with high cholesterol absorption efficiency.
Individual cholesterol absorption capacity and endo-
genous production varies due to genetic polymorphism.
Response to statins may be determined by the Apo E
genotype, by a possible effect on bile acid synthesis
and/or by variability in the rate of CYP metabolism.85
There are studies in patients with familial hypercholeste-
rolaemia86 and non-familiar hypercholesterolaemia87 that
suggest that statin treatment in those who display an E4
allele reduces LDL-c to a lesser degree than in indivi-
duals with E2 or E3 alleles. However, other studies have
not been able to confirm this hypothesis.87-90 Individuals
with the Apo E4 allele do, nevertheless, absorb more
cholesterol than those with other Apo E alleles.91 In a
study that measured cholesterol absorption and synthe-
sis in a group of Finns, those with an E2 allele (E2/2,
E2/3 or E2/4) absorbed less and synthesised more cho-
lesterol than those with an E3 (E3/3) allele. Individuals
with an E4 (E3/4 or E4/4) allele displayed the greatest
absorption and lowest synthesis.92 As well as by the Apo
E genotype, inter-individual differences in absorption
are influenced by polymorphisms of the ABC G5 and
G8 genes.91 Differences in the response to sterol esters in
mild hypercholesterolaemics have been found to be
dependently of ApoE polymorphisms.83 Patients carr-
ying the ApoE4 allele decreased less the total choleste-
rol, LDL-cholesterol and ApoB levels than their ApoE2
and ApoE 3 carrier counterparts.83
Statin treatment reduces cholesterol precursors and
increases serum phytosterol levels,93 particularly in
individuals with a high absorption capacity for choles-
terol and sterols in general. In the early 1990’s, some
studies with Pravastatin and Lovastatin reported incre-
ases in cholestanol and serum phytosterols,94-96 while
others described reductions.97 Serum concentrations of
phytosterols decrease with statin treatment for a varia-
ble period of time. Some studies indicate that this
reduction depends on their pre-treatment absorption
levels, treatment duration and the efficacy in inhibiting
cholesterol synthesis.85,97 Several studies deal with the
effect of sterol and stanol treatment on LDL-c levels in
individuals treated with statins (table V).98 The first
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Fig. 2.—Chemical structure of cholesterol
and main plant sterols.
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study that combined statins and stanols (1.5 g/day of
sitostanol ester), reported no significant decrease in
total cholesterol or LDL-c levels.99 Results of a later
study of individuals with non-insulin-dependent diabe-
tes mellitus treated with Pravastatin displayed an addi-
tional 6% decrease in LDL-c levels when these patients
were given sitostanol esters (3 g/day) in margarine,
even when initial cholesterol absorption was already
low.100 Even greater reductions (16-20%) were observed
in other studies although these were unblinded and
uncontrolled.101-102 Reductions in total cholesterol levels
of 11% and of LDL-c levels of 16% were obtained in
postmenopausal women who had previously suffered
myocardial infarction and were taking Simvastatin after
have been given a complementary treatment consisting
of sitostanol ester (3 g/day) in margarine.101 Serum LDL-
c levels decreased by 20% in individuals with familial
hypercholesterolaemia who were given Simvastatin
together with 2.24 g/day of stanols.102 LDL-c reductions
of 7-11% were reported in four-to-eight-week-long pla-
cebo-controlled, double-blind random studies with phy-
tosterol and/or phytostanol esters.103-107 In one of these
studies, 5.1 g/day of phytostanol ester in margarine in
conjunction with a stable statin treatment further redu-
ced total serum cholesterol levels by 7% and those of
LDL-c by 10%.91 Various studies have shown that phy-
tostanols103 and phytosterols105 have an additive, not a
synergic, effect when given together with statins to indi-
viduals with primary hypercholesterolaemia.105 The four
treatment options of this study were: placebo plus regu-
lar margarine, placebo plus phytosterol-enriched (2 g)
margarine, cerivastatin (400 μg) plus regular margarine
and cerivastatin (400 μg) plus phytosterol-enriched (2 g)
margarine. Cerivastatin vs. placebo reduced LDL-c by
32% and enriched margarine vs. regular margarine redu-
ced these levels by 8%. Phytosterol-enriched margarine
taken together with cerivastatin induced a 39% reduc-
tion but no significant interactive effect between phytos-
terol and statin was observed. With regard to the reduc-
tion of cholesterol levels through phytosterol or phytos-
tanol treatment some of the studies reviewed report no
statistical differences between hypercholesterolaemic
individuals treated with statins and non-treated hyper-
cholesterolaemics104 or normocholesterolaemic indivi-
duals.105
Few studies compare the efficacy of plant sterols and
stanols. The majority, lasting for only 3-4 weeks, reflect
insignificant differences in effectiveness. Differences
were detected, however, between the administration of
phytosterol esters (1.6 g/day) and phytostanol esters (1.6
g/day or 2.6 g/day) over a two-month-long period to
healthy individuals and to others with familial hypercho-
lesterolaemia receiving statin treatment.106 The effect of
the phytosterols decreased at the end of the study and
LDL-c level was not significantly different from base-
line. In addition, these individuals displayed an increase
in serum phytosterol levels and decrease bile acid synt-
hesis. In contrast, after the two-month-long treatment,
phytostanol esters significantly decreased both LDL-c
and phytosterol levels, without producing any effect on
bile acid synthesis.106
Taking into account all the information previously
reviewed, it is possible to conclude that phytostanol
esters with respect to phytosterol esters should be pre-
ferred for long-term treatment of hypercholesterolae-
mia. Various studies have confirmed that the additive
effect produced by combining phytostanols with a
small dose of statins reduces LDL-c levels by approxi-
mately 10%,84 this reduction is slightly greater than that
achieved by doubling the dose of statins.107 Further-
more, by lowering the dose of statins the risk of rhab-
domyolysis, which appears to be dose-dependent, also
decreases.108 In addition, a triple therapy including sta-
nol esters, statins and resins can reduce LDL-c by up to
67% and may be effective in the most resistant hyper-
cholesterolaemias.93
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Table V
Effect of phytosterols and phytostanols on LDL-c in individuals treated with statins
Dose Time Δ LDL-c (%)Reference Subjects (n) Statins Esters of (g/day) (weeks) vs
statin plus placebo
Vanhanen99 FH (13) Pravastatin Sitostanol 1,5 6 0
HC (14)
Gylling and Miettinen100 HC-NIDDM (8) Pravastatin Sitostanol 3 7 -6
Gylling et al.101 PMW-MI Simvastatin Sitostanol 3 7 -16(*)
Vuori et al.102 FH (12) Simvastatin Stanols 2,2 6 -20(*)
Blair et al.103 HC (148) Various Stanols 3 8 -10
Neil et al.104 FH (30) Various Sterols 2,5 8 -11
Simons.105 HC (75) Cerivastatin Sterols 2 4 -7
O’Neill et al.106 FH (25) Various Stanols 2,6 8 -7
FH, Familial hypercholesterolaemia; HC, hypercholesterolaemia; NIDDM, non-insulin-dependent diabetes mellitus; PMW-MI, postmenopausal women with a previous
myocardial infarction; (*) uncontrolled studies. Udapted from Thompson.98
Conclusions and future remarks
This article reviews some outstanding aspects of the
interactions between statins and dietary components. The
most relevant results were those obtained with grapefruit
juice, oily fish and phytosterols. Given the risk of statin-
induced adverse reactions (e.g. myopathy and rhabdom-
yolysis), a close monitorisation of patients receiving sta-
tin treatment is necessary. Concomitant administration of
this group of drugs with certain foods can lead to a reduc-
tion (in the case of fibre) or an increase (with grapefruit
juice, n-3 fatty acids, phytosterols) of their pharmacolo-
gical action. Therefore, to optimise the pharmacological
treatment, it is necessary to understand and adjust certain
important aspects of the diet of these patients. Besides,
follow-up studies of the therapeutic effects of statins in
patients consuming a Mediterranean diet, which includes
high levels of fibre, citric fruits, oily fish, phytosterols,
olive oil rich in polyphenols and other minor compo-
nents, are necessary to assure the correct prescription and
dosage of statins in these individuals. To conclude, we
emphasize that there are possible interactions that require
further investigation, for example, different types of oils
—e.g. poor and rich in minor compounds olive oils—,
fruit juices or fibre, or the prolonged consumption of high
doses of alcohol.
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